To validate the anti-tumorigenic efficacy of GMI in vivo, immunocompromised mice bearing OCSC xenografts received GMI treatment or vehicle by oral gavage followed by analyses of tumor volume and expression of phosphorylated-Stat3 in tumors. The gene discussed is STAT3; the disease is neoplasm.